PAMP
ACAD icon

Polar Asset Management Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Polar Asset Management Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-107,700
Closed -$2.24M – 789
2023
Q3 		$2.24M Buy
+107,700
New +$2.93M 0.05% 371

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Polar Asset Management Partners's ACAD Position: Q4 2023 in Review

Polar Asset Management Partners sold out of Acadia Pharmaceuticals (ACAD) in Q4 2023, closing a stake of 107,700 shares — an estimated $2.24M sold.

Polar Asset Management Partners first reported a position in ACAD in Q3 2023 and held it in 1 quarter. The position peaked at $2.24M in Q3 2023. 276 funds tracked by Wall St. Rank hold ACAD as of Q4 2023.

  • Polar Asset Management Partners reported no remaining Acadia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Polar Asset Management Partners sold 107,700 Acadia Pharmaceuticals shares in Q4 2023, an estimated $2.24M.
  • Polar Asset Management Partners first reported a position in Acadia Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Polar Asset Management Partners's Acadia Pharmaceuticals position peaked at $2.24M in Q3 2023.
  • 276 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2023.

Based on Polar Asset Management Partners's 13F filing for Q4 2023, filed 14 Feb 2024.